Search review questions

Progression‐free survival Defined as time from randomisation to progression either on or off treatment (Illustrative comparative risks reported as number of participants without progression) · adults with cancer receiving anthracyclines

Tumour response rate Defined as number of complete or partial remissions Available‐case analysis · adults with cancer receiving anthracyclines

Quality of life · adults with cancer receiving anthracyclines

Event‐free survival (reported as number of participants with progression, relapse, second malignancy, or death, whatever the cause) · children, adolescents, and young adults with primary metastatic Ewing sarcoma

Overall survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma

Quality‐adjusted survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma

Toxicity · children, adolescents, and young adults with primary metastatic Ewing sarcoma

Progression‐free survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma

Hearing loss (asymptomatic and symptomatic disease according to Brock criteria) exact instrument used to test hearing loss was not reported · children with cancer treated with platinum‐based therapy

Tinnitus ‐ not reported · children with cancer treated with platinum‐based therapy

Overall survival ‐ not reported · children with cancer treated with platinum‐based therapy

Event‐free survival ‐ not reported · children with cancer treated with platinum‐based therapy

Tumour response (complete or partial remission according to INRC) · children with cancer treated with platinum‐based therapy

Adverse effects: toxic death (no definition provided) · children with cancer treated with platinum‐based therapy

Quality of life ‐ not reported · children with cancer treated with platinum‐based therapy

Ototoxicity according to NCICTCv2 criteria with intra‐arterial platinum (combined asymptomatic and symptomatic disease) Exact test method not reported · children with cancer treated with platinum‐based therapy

Quality of life – not reported · children with cancer treated with platinum‐based therapy

Ototoxicity according to Brock criteria with intravenous platinum (combined asymptomatic and symptomatic disease) · children with cancer treated with platinum‐based therapy

Survival · children with cancer treated with platinum‐based therapy

Overall survival with intravenous platinum (i.e. mortality/number of participants deceased) · children with cancer treated with platinum‐based therapy

Event‐free survival with intravenous platinum (i.e. number of participants with disease progression, disease relapse, second primary cancer or death) · children with cancer treated with platinum‐based therapy

Tumour response · children with cancer treated with platinum‐based therapy

Tumour response with intravenous platinum (complete and partial remission) · children with cancer treated with platinum‐based therapy

Adverse effects other than ototoxicity (≥ grade 3 according to NCICTCAEv3 criteria) with intravenous platinum · children with cancer treated with platinum‐based therapy

Quality of life · children with cancer treated with platinum‐based therapy

Quality of life – not reported · children with cancer treated with platinum‐based therapy

Ototoxicity according to NCICTCv2 criteria with intravenous platinum (combined asymptomatic and symptomatic disease) Objective and subjective audiometric evaluations were performed, no further information provided · children with cancer treated with platinum‐based therapy

Ototoxicity according to modified Brock criteria with intravenous platinum (combined asymptomatic and symptomatic disease) Audiograms were performed, but no further information provided · children with cancer treated with platinum‐based therapy

Survival · children with cancer treated with platinum‐based therapy

Survival (overall and event‐free) – not reported · children with cancer treated with platinum‐based therapy

Tumour response · children with cancer treated with platinum‐based therapy

Tumour response with intra‐arterial platinum (good and partial remission) · children with cancer treated with platinum‐based therapy

Renal toxicity/vomiting/ cardiotoxicity (all grade ≥ 3 according to NCICTCv2 criteria) with intra‐arterial platinum · children with cancer treated with platinum‐based therapy

Quality of life · children with cancer treated with platinum‐based therapy

Overall survival (reported as mortality) · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

Treatment‐related mortality ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

Progression‐free survival ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

Event‐free survival (reported as relapse, progressive disease, secondary cancer, and mortality) · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

Early toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

Late non‐haematological toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

Health‐related quality of life ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

Incidence of clinical tumour lysis syndrome ( · children with haematological malignancy at risk of tumour lysis syndrome

Renal failure requiring renal replacement therapy · children with haematological malignancy at risk of tumour lysis syndrome

Normalisation of serum uric acid ( · children with haematological malignancy at risk of tumour lysis syndrome

Percentage reduction in serum uric acid level at 4 hours ( · children with haematological malignancy at risk of tumour lysis syndrome

AUC of serum uric acid level · children with haematological malignancy at risk of tumour lysis syndrome

Frequency of adverse events ( · children with haematological malignancy at risk of tumour lysis syndrome

Mortality due to tumour lysis syndrome ( · children with haematological malignancy at risk of tumour lysis syndrome

Renal failure requiring renal replacement therapy ( · children with haematological malignancy at risk of tumour lysis syndrome

Normalisation of serum uric acid · children with haematological malignancy at risk of tumour lysis syndrome